Immune response to hepatitis B vaccine with high antigen content in non-responders after standard primary vaccination in Chinese adults

Vaccine

Volumn 32, Issue 29, 2014, Pages 3706-3712

  Pan, Hong Xing ^a   Zeng, Ying ^b   Song, Xue Fang ^b   Zhang, Yi Ju ^a   Xu, Ke ^a   Liang, Zheng Lun ^c   Zhu, Feng Cai ^a  

^a JIANGSU PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b Shenzhen Kangtai Biological Products Co Ltd   (China)

^c NATIONAL INSTITUTES FOR FOOD AND DRUG CONTROL   (China)

Author keywords

Hepatitis B vaccine with high antigen content; Hepatitis B virus; Immunogenicity; Non responder

Indexed keywords

ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIGEN; RECOMBINANT VACCINE;

ADOLESCENT; ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; ERYTHEMA; FEMALE; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION PAIN; INJECTION SITE REACTION; MALE; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RHINOSCLEROMA; SEROCONVERSION; TREATMENT RESPONSE; VACCINATION; ANTIBODY PRODUCTION; BLOOD; CLINICAL TRIAL; IMMUNIZATION; IMMUNOLOGY; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODY FORMATION; DOUBLE-BLIND METHOD; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; MALE; MIDDLE AGED; VACCINES, SYNTHETIC; YOUNG ADULT;

EID: 84901641016     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.02.094     Document Type: Article

References (21)

1. World Health Organization Hepatitis B. Fact sheet no. 204 July, 2012, http://www.who.int/mediacentre/factsheets/fs204/en/index.html (accessed May 10, 2014).
2. Centers for Disease Control and Prevention, 〈http://www.cdc.gov/hepatitis/B/bFAQ.htm#overview〉 (accessed May 10, 2014).
3. Liang X., Bi S., Yang W., Wang L., Cui G., Cui F., et al. Epidemiological serosurvey of hepatitis B in China-declining HBV prevalence due to hepatitis B vaccination. Vaccine 2009, 27:6550-6557.
4. Jack A.D., Hall A.J., Maine N., Mendy M., Whittle H.C. What level of hepatitis B antibody is protective. J Infect Dis 1999, 179:489-492.
5. Das K., Gupta R.K., Kumar V., Kar P. Immunogenicity and reactogenicity of a recombinant hepatitis B vaccine in subjects over age forty years and response of a booster dose among nonresponders. World J Gastroenterol 2003, 9:1132-1134.
6. Wood R.C., MacDonald K.L., White K.E., Hedberg C.W., Hanson M., Osterholm M.T. Risk factors for lack of detectable antibody response following hepatitis B vaccination of Minnesota health care workers. JAMA 1993, 270:2935-2939.
7. Rendi-Wagner P., Shouval D., Genton B., Lurie Y., Rümke H., Boland G., et al. Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine. Vaccine 2006, 24:2781-2789.
8. Cardell K., Akerlind B., Sällberg M., Frydén A. Excellent response rate to a double dose of the combined hepatitis A and B vaccine in previous nonresponders to hepatitis B vaccine. J Infect Dis 2008, 198:299-304.
9. Psevdos G., Kim J.H., Groce V., Sharp V. Efficacy of double-dose hepatitis B rescue vaccination in HIV-infected patients. AIDS Patient Care STDS 2010, 24:403-407.
10. Notice the standard guidelines for adverse reactions grading of vaccine clinical trials, (accessed May 10, 2014). http://www.sda.gov.cn/WS01/CL1036/9350_5.html.
11. Zeeshan M., Jabeen K., Ali A.N., Ali A.W., Farooqui S.Z., Mehraj V., Zafar A. Evaluation of immune response to hepatitis B vaccine in health care workers at a tertiary care hospital in Pakistan: an observational prospective study. BMC Infect Dis 2007, 7:120.
12. Clemens R., Sanger R., Kruppenbacher J., Hobel W., Stanbury W., Bock H.L., et al. Booster immunization of low- and non-responders after a standard three dose hepatitis B vaccine schedule-results of a post-marketing surveillance. Vaccine 1997, 15:349-352.
13. Playford E.G., Hogan P.G., Bansal A.S., Harrison K., Drummond D., Looke D.F., et al. Intradermal recombinant hepatitis B vaccine for healthcare workers who fail to respond to intramuscular vaccine. Infect Control Hosp Epidemiol 2002, 23:87-90.
14. Das H.S., Sawant P., Shirhatti R.G., Vyas K., Vispute S., Dhadpale S., et al. Efficacy of low dose intradermal hepatitis B vaccine: results of a randomized trial among healthcare workers. Trop Gastroenterol 2002, 23:120-121.
15. Poland G.A. Hepatitis B immunization in health care workers: dealing with vaccine nonresponse. Am J Prev Med 1998, 15:73-77.
16. Sjogren M.H. Prevention of hepatitis B in nonresponders to initial hepatitis B virus vaccination. Am J Med 2005, 34S-39S.
17. Ural O., Findik D. The response of isolated anti-HBc positive subjects to recombinant hepatitis B vaccine. J Infect 2001, 43:187-190.
18. Yen Y.H., Chen C.H., Wang J.H., Lee C.M., Changchien C.S., Lu S.N. Study of hepatitis B (HB) vaccine non-responsiveness among health care workers from an endemic area (Taiwan). Liver Int 2005, 25:1162-1168.
19. Wu Q., Zhuang G.H., Wang X.L., Wang L.R., Li N., Zhang M. Antibody levels and immune memory 23 years after primary plasma-derived hepatitis B vaccination: results of a randomized placebo-controlled trial cohort from China where endemicity is high. Vaccine 2011, 29:2302-2307.
20. Centers for Disease Control and Prevention, 〈http://www.cdc.gov/hepatitis/hbv/pdfs/serologicchartv8.pdf〉 (accessed May 10, 2014).
21. Su F.H., Bai C.H., Chu F.Y., Lin Y.S., Su C.T., Yeh C.C. Significance and anamnestic response in isolated hepatitis B core antibody-positive individuals 18 years after neonatal hepatitis B virus vaccination in Taiwan. Vaccine 2012, 30:4034-4039.